These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 33157015)

  • 1. Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program.
    Bieging-Rolett KT; Kaiser AM; Morgens DW; Boutelle AM; Seoane JA; Van Nostrand EL; Zhu C; Houlihan SL; Mello SS; Yee BA; McClendon J; Pierce SE; Winters IP; Wang M; Connolly AJ; Lowe SW; Curtis C; Yeo GW; Winslow MM; Bassik MC; Attardi LD
    Mol Cell; 2020 Nov; 80(3):452-469.e9. PubMed ID: 33157015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p53-induced RNA-binding protein ZMAT3 is a splicing regulator that inhibits the splicing of oncogenic CD44 variants in colorectal carcinoma.
    Muys BR; Anastasakis DG; Claypool D; Pongor L; Li XL; Grammatikakis I; Liu M; Wang X; Prasanth KV; Aladjem MI; Lal A; Hafner M
    Genes Dev; 2021 Jan; 35(1-2):102-116. PubMed ID: 33334821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zmat3 splices together p53-dependent tumor suppression.
    Bieging-Rolett KT; Attardi LD
    Mol Cell Oncol; 2021; 8(3):1898523. PubMed ID: 34027039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative multiomic approaches reveal ZMAT3 and p21 as conserved hubs in the p53 tumor suppression network.
    Boutelle AM; Mabene AR; Yao D; Xu H; Wang M; Tang YJ; Lopez SS; Sinha S; Demeter J; Cheng R; Benard BA; Valente LJ; Drainas AP; Fischer M; Majeti R; Petrov DA; Jackson PK; Yang F; Winslow MM; Bassik MC; Attardi LD
    bioRxiv; 2024 Sep; ():. PubMed ID: 39345444
    [No Abstract]   [Full Text] [Related]  

  • 5. Consequences of Zmat3 loss in c-MYC- and mutant KRAS-driven tumorigenesis.
    Best SA; Vandenberg CJ; Abad E; Whitehead L; Guiu L; Ding S; Brennan MS; Strasser A; Herold MJ; Sutherland KD; Janic A
    Cell Death Dis; 2020 Oct; 11(10):877. PubMed ID: 33082333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice.
    Brennan MS; Brinkmann K; Romero Sola G; Healey G; Gibson L; Gangoda L; Potts MA; Lieschke E; Wilcox S; Strasser A; Herold MJ; Janic A
    Cell Death Differ; 2024 Feb; 31(2):159-169. PubMed ID: 38110554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ribosomal protein L22 binds the MDM4 pre-mRNA and promotes exon skipping to activate p53 upon nucleolar stress.
    Jansen J; Bohnsack KE; Böhlken-Fascher S; Bohnsack MT; Dobbelstein M
    Cell Rep; 2024 Aug; 43(8):114610. PubMed ID: 39116201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of splicing factor SRSF3 induces p53β, an alternatively spliced isoform of p53 that promotes cellular senescence.
    Tang Y; Horikawa I; Ajiro M; Robles AI; Fujita K; Mondal AM; Stauffer JK; Zheng ZM; Harris CC
    Oncogene; 2013 May; 32(22):2792-8. PubMed ID: 22777358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4.
    Weinstein HNW; Hu K; Fish L; Chen YA; Allegakoen P; Pham JH; Hui KSF; Chang CH; Tutar M; Benitez-Rivera L; Baco MB; Song H; Giacomelli AO; Vazquez F; Ghandi M; Goodarzi H; Huang FW
    Cell Rep; 2024 Aug; 43(8):114622. PubMed ID: 39146182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression.
    Indeglia A; Murphy ME
    Crit Rev Biochem Mol Biol; 2024; 59(1-2):128-138. PubMed ID: 38661126
    [No Abstract]   [Full Text] [Related]  

  • 12. RBM10, a New Regulator of p53.
    Jung JH; Lee H; Zeng SX; Lu H
    Cells; 2020 Sep; 9(9):. PubMed ID: 32947864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of nonsense-mediated mRNA decay pathway as a critical regulator of p53 isoform β.
    Cowen LE; Tang Y
    Sci Rep; 2017 Dec; 7(1):17535. PubMed ID: 29235495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer.
    Escobar-Hoyos LF; Penson A; Kannan R; Cho H; Pan CH; Singh RK; Apken LH; Hobbs GA; Luo R; Lecomte N; Babu S; Pan FC; Alonso-Curbelo D; Morris JP; Askan G; Grbovic-Huezo O; Ogrodowski P; Bermeo J; Saglimbeni J; Cruz CD; Ho YJ; Lawrence SA; Melchor JP; Goda GA; Bai K; Pastore A; Hogg SJ; Raghavan S; Bailey P; Chang DK; Biankin A; Shroyer KR; Wolpin BM; Aguirre AJ; Ventura A; Taylor B; Der CJ; Dominguez D; Kümmel D; Oeckinghaus A; Lowe SW; Bradley RK; Abdel-Wahab O; Leach SD
    Cancer Cell; 2020 Aug; 38(2):198-211.e8. PubMed ID: 32559497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.
    Yano K; Takahashi RU; Shiotani B; Abe J; Shidooka T; Sudo Y; Yamamoto Y; Kan S; Sakagami H; Tahara H
    J Biol Chem; 2021 Jul; 297(1):100882. PubMed ID: 34144037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
    Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
    Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.
    Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW
    Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1.
    Yuan JH; Liu XN; Wang TT; Pan W; Tao QF; Zhou WP; Wang F; Sun SH
    Nat Cell Biol; 2017 Jul; 19(7):820-832. PubMed ID: 28553938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SRSF2 Regulation of
    Comiskey DF; Montes M; Khurshid S; Singh RK; Chandler DS
    Mol Cancer Res; 2020 Feb; 18(2):194-203. PubMed ID: 31662450
    [No Abstract]   [Full Text] [Related]  

  • 20. Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo.
    He X; Liu F; Yan J; Zhang Y; Yan J; Shang H; Dou Q; Zhao Q; Song Y
    Sci Rep; 2015 Mar; 5():8705. PubMed ID: 25732051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.